Harmony Biosciences vs Repligen
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Harmony Biosciences and Repligen side by side, using each one’s latest annual report. Here is what stands out:
- Harmony Biosciences is the larger business, with $869M of revenue in fiscal 2025 against $738M for Repligen.
- Harmony Biosciences grew revenue faster (21.5%, against 16.4%).
- Harmony Biosciences kept more of each dollar of sales as operating profit (24.0% operating margin, against 7.5%).
- Harmony Biosciences turned more of its sales into free cash flow (40.1% FCF margin, against 12.7%).
- Harmony Biosciences earned a higher return on the capital invested in it (48.9%, against 2.4%).
Who comes out ahead
Of the 8 measures where higher (or lower) is clearly better, how many each company leads.
Harmony Biosciences
HRMY
8/8
Revenue growth5-year growthGross marginOperating marginNet marginFCF marginReturn on capitalReturn on equity
Repligen
RGEN
0/8
Side by side
Best in the row
| Latest fiscal year | HRMY FY25 | RGEN FY25 |
|---|---|---|
| Size | ||
| Market cap | $2.2B | — |
| Revenue | $869M | $738M |
| Free cash flow | $348M | $93.9M |
| Net income | $159M | $48.9M |
| Growth | ||
| Revenue growth | 21.5% | 16.4% |
| 5-year growth | 40.3% | 15.1% |
| Share count change | 1.2% | — |
| Profitability | ||
| Gross margin | 77.2% | 52.3% |
| Operating margin | 24.0% | 7.5% |
| Net margin | 18.3% | 6.6% |
| FCF margin | 40.1% | 12.7% |
| Return on capital | 48.9% | 2.4% |
| Return on equity | 20.8% | 2.4% |
| Balance sheet | ||
| Net debt | −$612M | −$225M |
| Net debt / EBITDA | — | −1.7x |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | 11.9x | — |
| Piotroski F-score | 5 | — |
Ten years
Revenue
FY16
HRMY —
RGEN $105M
FY17
HRMY —
RGEN $141M
FY18
HRMY —
RGEN $194M
FY19
HRMY $6.0M
RGEN $270M
FY20
HRMY $160M
RGEN $366M
FY21
HRMY $305M
RGEN $671M
FY22
HRMY $438M
RGEN $802M
FY23
HRMY $582M
RGEN $632M
FY24
HRMY $715M
RGEN $634M
FY25
HRMY $869M
RGEN $738M
HRMY
RGEN
Operating margin
FY16
HRMY —
RGEN 15.3%
FY17
HRMY —
RGEN 9.9%
FY18
HRMY —
RGEN 13.4%
FY19
HRMY −2,433.8%
RGEN 13.4%
FY20
HRMY 10.6%
RGEN 19.1%
FY21
HRMY 28.7%
RGEN 24.9%
FY22
HRMY 27.5%
RGEN 28.0%
FY23
HRMY 33.0%
RGEN 7.5%
FY24
HRMY 26.7%
RGEN −5.5%
FY25
HRMY 24.0%
RGEN 7.5%
HRMY
RGEN
Free cash flow
FY16
HRMY —
RGEN $3.2M
FY17
HRMY —
RGEN $12.0M
FY18
HRMY —
RGEN $22.1M
FY19
HRMY −$75.6M
RGEN $48.7M
FY20
HRMY −$3.0M
RGEN $40.2M
FY21
HRMY $98.3M
RGEN $51.9M
FY22
HRMY $144M
RGEN $87.3M
FY23
HRMY $219M
RGEN $77.7M
FY24
HRMY $219M
RGEN $150M
FY25
HRMY $348M
RGEN $93.9M
HRMY
RGEN
Return on capital
FY16
HRMY —
RGEN 15.2%
FY17
HRMY —
RGEN 4.3%
FY18
HRMY —
RGEN 3.9%
FY19
HRMY —
RGEN 4.6%
FY20
HRMY —
RGEN 7.7%
FY21
HRMY 78.2%
RGEN 11.4%
FY22
HRMY 57.8%
RGEN 12.4%
FY23
HRMY 49.3%
RGEN 1.7%
FY24
HRMY 42.7%
RGEN −1.6%
FY25
HRMY 48.9%
RGEN 2.4%
HRMY
RGEN
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.